Japan 7MM Digital Therapeutics for Diabetes Market to hit US$ 77.35 Million by 2033 | Top Companies - Welldoc Inc., Omada Health Inc., Glooko Inc.

Leander, Texas and Tokyo, Japan - Dec.24.2025
As per DataM intelligence research report" The 7MM Digital Therapeutics for Diabetes Market size reached US$ 961.09 million in 2024 and is expected to reach US$ 2,578.46 million by 2033, growing at a CAGR of 11.7% during the forecast period 2025-2033." Rising diabetes prevalence and evidence-based digital care models are driving adoption of digital therapeutics in major markets.

Download your exclusive sample report today: (corporate email gets priority access):
https://www.datamintelligence.com/download-sample/7mm-digital-therapeutics-for-diabetes-market?prasad

United States: Recent Industry Developments

✅ In November 2025, Better Therapeutics received expanded FDA indication for its CBT-based app for Type 2 diabetes The app addresses behavioral root causes to lower A1c levels alongside medication It integrates behavioral health into standard U.S. diabetes care

✅ In October 2025, Omada Health announced new data showing sustained remission in patients using its virtual care program The program combines GLP-1 support with digital coaching to maintain weight loss It adapts DTx strategies to the era of effective obesity drugs in the U.S.

✅ In September 2025, DarioHealth partnered with a major U.S. health plan to offer its metabolic solution The partnership bundles glucose monitoring with AI-driven guidance It focuses on reducing the total cost of care for diabetic members

✅ In August 2025, Welldoc integrated continuous glucose monitor (CGM) data into its "BlueStar" platform The integration provides real-time feedback on food and activity choices It enhances the utility of prescription apps for U.S. insulin users

Japan: Recent Industry Developments

✅ In December 2025, CureApp received regulatory approval for a DTx treating hypertension, a key comorbidity of diabetes The app is the first of its kind to be reimbursed by Japan's national health insurance It paves the way for future standalone diabetes digital therapeutics

✅ In November 2025, Terumo Corporation launched a digital patient support program for insulin users The platform connects patients with nurses via chat to adjust doses and lifestyle It supports the "task shifting" initiative in Japanese healthcare

✅ In October 2025, Save Medical initiated a clinical trial for a Type 2 diabetes management app The app focuses on diet and exercise modification specifically for the Japanese lifestyle It aims to provide a non-pharmacological treatment option

✅ In September 2025, Astellas Pharma partnered with Welldoc to commercialize "BlueStar" in Japan The partnership adapts the U.S. app to Japanese language and clinical guidelines It brings global DTx innovation to the Japanese market

7MM Digital Therapeutics for Diabetes Market: Drivers
The digital therapeutics for diabetes market is driven by rising global prevalence of diabetes. Healthcare systems are adopting digital tools for long-term disease management. Digital therapeutics support behavior modification and medication adherence. Increasing smartphone penetration is improving accessibility. Growing focus on personalized care is strengthening adoption. Cost-effective management solutions are driving demand.

Another key driver is the integration of AI and data analytics in diabetes care. Real-time monitoring improves glycemic control. Growing acceptance of remote patient management is supporting market growth. Regulatory recognition of digital therapeutics is improving credibility. Partnerships between tech and healthcare companies are expanding solutions. These factors are driving steady expansion.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/7mm-digital-therapeutics-for-diabetes-market?prasad

7MM Digital Therapeutics for Diabetes Market: Major Players
Welldoc, Inc., Omada Health Inc., Glooko, Inc., Azumio Inc., Abbott Laboratories, mySugr GmbH, Dexcom, Inc., Health2Sync, iHealth Labs Inc. and Medtronic plc and among others.

Segment Covered in the 7MM Digital Therapeutics for Diabetes Market:
By Product Type
The market is segmented into mobile-based digital therapeutics applications (50%), software platforms integrated with devices (30%), and web-based therapeutic solutions (20%). Mobile-based digital therapeutics dominate due to widespread smartphone usage and strong patient engagement through real-time monitoring, coaching, and personalized feedback. Software platforms integrated with glucose monitors and insulin delivery devices are gaining traction as part of comprehensive diabetes management ecosystems. Web-based solutions are primarily adopted for structured education programs and clinician dashboards.

By Application
Applications include type 2 diabetes management (65%), type 1 diabetes management (25%), and prediabetes management (10%). Type 2 diabetes leads the market due to its high prevalence across the 7MM countries and strong evidence supporting digital therapeutics in lifestyle modification, medication adherence, and glycemic control. Type 1 diabetes adoption is growing with increasing integration of digital therapeutics with continuous glucose monitoring (CGM) and insulin delivery systems. Prediabetes applications focus on early intervention and prevention.

By End-User
End-users comprise patients/consumers (55%), healthcare providers (25%), and payers/employers (20%). Patients represent the largest segment, driven by demand for self-management tools and remote care solutions. Healthcare providers adopt digital therapeutics to improve clinical outcomes, enhance patient monitoring, and reduce in-person visits. Payers and employers are increasingly adopting these solutions to lower long-term diabetes-related healthcare costs.

Regional Analysis
United States - 45% Share
The U.S. dominates the 7MM market due to high diabetes prevalence, strong digital health ecosystem, favorable reimbursement developments, and early adoption of FDA-cleared digital therapeutics. Employer-sponsored programs and payer partnerships further accelerate adoption.

Europe (EU5) - 35% Share
Europe holds a significant share driven by growing acceptance of prescription digital therapeutics, particularly in Germany under the DiGA framework. The U.K., France, Italy, and Spain show increasing adoption supported by national healthcare systems, remote care initiatives, and rising focus on chronic disease management.

Japan - 20% Share
Japan shows steady growth due to an aging population, increasing diabetes burden, and government support for digital health innovation. Integration of digital therapeutics with existing healthcare infrastructure and strong emphasis on preventive care support market expansion.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=7mm-digital-therapeutics-for-diabetes-market
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?prasad

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.